Historical Controls?
Open Access
- 28 February 2017
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 102 (3) , e117
Abstract
As noted by Gökbuget and colleagues,[1][1] licensing agencies increasingly depend on the results of single arm phase II trials.[2][2] As attention focuses on small, molecularly defined, patient subsets, urgent clinical need, and eagerness to test scientifically compelling targeted agents encourageKeywords
This publication has 10 references indexed in Scilit:
- Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemiaBlood Cancer Journal, 2016
- International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemiaHaematologica, 2016
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2016
- Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of CrizotinibClinical and Translational Science, 2016
- Re-Induction Outcome for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Therapeutic Advances in Childhood Leukemia ConsortiumBlood, 2015
- The role of nonrandomized trials in the evaluation of oncology drugsClinical Pharmacology & Therapeutics, 2015
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2015
- Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium StudyJournal of Clinical Oncology, 2010
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesBlood, 2009
- Evaluating Glioma Therapies: Modeling Treatments and Predicting OutcomesJNCI: Journal of the National Cancer Institute, 1995